Identification of early predictors of clinical remission in primary membranous nephropathy: a post hoc analysis of the STARMEN trial
Clinical Kidney Journal · 01.09.2025 · 18 (9)
DOI: 10.1093/ckj/sfaf256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 13.08.2025. Verfasst von Jorge E Rojas-Rivera und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Hypertension, Hospital Universitario Fundación Jiménez Díaz & Current Visiting Research Scholar, The Ohio State Universi…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional.
Abstract (Originalsprache)
Background
Patients with primary membranous nephropathy may progress to advanced chronic kidney disease despite immunosuppressive therapy (IST). Prediction of treatment response based on early and combined assessment of several standard clinical markers could improve risk stratification for progression, allowing timely individualization of treatment, which can optimize clinical outcomes and safety.
Methods
In this post hoc exploratory analysis of the STARMEN trial, we evaluated if combined baseline data, and IST-induced early changes in standard clinical markers predicted clinical remission at 2 years. The 2-year primary outcome was complete (CR) or partial remission (PR). The secondary outcome was CR. Additionally, we described kidney function outcomes. Standard clinical markers were incorporated into statistical modeling by logistic regression. Predictive performance was assessed by receiver operating characteristic curve analysis.
Results
The best multivariate model excluding immunosuppression to predict complete or PR at 2 years, included 3-month 24-h proteinuria, serum creatinine and immunological response [area under the curve (AUC) 0.87, 95% confidence interval (CI) 0.76–0.94, efficiency 87%]. For CR at 2 years, the best model included the same clinical markers at 6 months, but predictive performance was lower (AUC 0.74, 95% CI 0.62–0.85, efficiency 70%).
Conclusions
In the STARMEN cohort, a multivariable model that included 24-h proteinuria, serum creatinine and immunological response status at 3 months after initiation of IST predicted clinical remission at 2 years with significantly better predictive performance than baseline data or each clinical marker assessed separately.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology and Hypertension, Hospital Universitario Fundación Jiménez Díaz & Current Visiting Research Scholar, The Ohio State University - Wexner Medical Center, Columbus, OH, USA.
- Universidad Autónoma de Madrid, Madrid, Spain.
- Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Department of Nephrology, Radboud Institute of Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
- Department of Nephrology, Hospital Universitario La Paz, Madrid, Spain.
- Department of Nephrology, Hospital Universitario Doctor Peset, Valencia, Spain.
ORCID-Profile: Jorge E Rojas-Rivera, Fernando Caravaca-Fontán, Amir Shabaka, Alberto Ortiz, Luis F Quintana, Montserrat Diaz, Pierre Ronco, Manuel Praga
Förderung
- Instituto de Salud Carlos III
- Fondo Europeo de Desarrollo Regional
Zitieren
APA
Rojas-Rivera, J. E., Caravaca-Fontán, F., van de Logt, A. E., Sevillano, A., Shabaka, A., Ávila, A., Rabasco, C., Cabello, V., Ortiz, A., Quintana, L. F., Goicoechea, M., Diaz, M., Ronco, P., Wetzels, J., Fernández-Juárez, G., & Praga, M. (2025). Identification of early predictors of clinical remission in primary membranous nephropathy: a post hoc analysis of the STARMEN trial. Clinical Kidney Journal, 18(9). https://doi.org/10.1093/ckj/sfaf256
Vancouver
Rojas-Rivera JE, Caravaca-Fontán F, van de Logt AE, Sevillano A, Shabaka A, Ávila A, et al. Identification of early predictors of clinical remission in primary membranous nephropathy: a post hoc analysis of the STARMEN trial. Clinical Kidney Journal. 2025;18(9). doi:10.1093/ckj/sfaf256
BibTeX
@article{RojasRivera2025,
author = {Rojas-Rivera, Jorge E and Caravaca-Fontán, Fernando and van de Logt, Anne-Els and Sevillano, Angel and Shabaka, Amir and Ávila, Ana and Rabasco, Cristina and Cabello, Virginia and Ortiz, Alberto and Quintana, Luis F and Goicoechea, Marian and Diaz, Montserrat and Ronco, Pierre and Wetzels, Jack and Fernández-Juárez, Gema and Praga, Manuel},
title = {Identification of early predictors of clinical remission in primary membranous nephropathy: a post hoc analysis of the STARMEN trial},
journal = {Clinical Kidney Journal},
year = {2025},
volume = {18},
number = {9},
doi = {10.1093/ckj/sfaf256}
}
EUVIMED